The UK’s long-standing leadership in medical research is now in serious question as the commercial environment for developing and selling new drugs continues to deteriorate. While the country’s scientists remain world-class, the system that supports turning their discoveries into treatments is failing, according to top industry figures.
This warning comes as major pharmaceutical companies, the lifeblood of late-stage research, are actively disinvesting. Sanofi has cut its UK clinical trials—the critical phase of medical research—by 50%. MSD has scrapped a massive £1bn R&D facility, and Eli Lilly has paused a lab designed to nurture new biotechs.
The problem, as articulated by executives, is that the UK is no longer a good place to do the expensive “development work” that follows basic research. Uncompetitive drug prices and high operating costs mean that companies are choosing to conduct this work in the US and other more favorable markets.
If this trend continues, the UK risks becoming a country of great ideas with no capacity to develop them. This threatens not only a key sector of the economy but also the future of the NHS’s access to innovative medicines, putting the nation’s scientific reputation at a critical crossroads.